GW Pharmaceuticals Plc (OTCMKTS:GWPRF) clocked weekly gains of 10% on reporting impressive results and on the news of Epidiolex, a famed drug. It beat the analysts’ expectations and posted better than expected results in the latest quarter.
Impressive sales of Epidiolex
GW Pharmaceuticals posted impressive sales of Epidiolex, a cannabis derived drug. The FDA approved drug is used for the treatment of childhood epilepsy. The company began the sales of Epidiolex in November 2018. The drug contributed sales of $33.5 million of the total sales of $39.5 million of GW Pharmaceuticals.
Phase 3 trial of Epidiolex
GW Pharmaceuticals is pleased to announce positive results of Epidiolex during phase 3 clinical trial. The company conducted phase 3 trial to test the effectiveness of Epidiolex in treating patients suffering from TSC (Tuberous Sclerosis Complex), a severe epilepsy in the childhood.
The drug has shown a considerable reduction in the seizure frequency from the baseline than placebo during the trial. It is the 5th consecutive trial for the drug and reiterates the success. GW Pharmaceuticals plans for the launch of an oral solution – Epidiolex in the five major markets of Europe in the later part of 2019.
The CEO of GW Pharmaceuticals, Justin Gover will be present in Las Vegas on May 15, 2019, Wednesday at the BOA (Bank of America) Merrill Lynch Healthcare Conference.
GW Pharmaceuticals and Greenwich Biosciences, the US subsidiary, will showcase the phase 3 clinical trials of oral solution – Epiodiolex at AAN (American Academy of Neurology) annual conference in Philadelphia on May 4, 2019. The company will present the effectiveness of the drug in treating Dravet Syndrome and Lennox Gastaut syndrome with supporting data.
Justin Gover said the community in the US has well accepted the drug to treat seizures. It is a highly purified cannabidiol sold on prescription.
Epidiolex is not recommended for people, who are allergic to any ingredients in this oral solution or CBD. The physician prescribes blood test of the patients to check the health of liver before and after the usage of Epidiolex. The patients need to seek urgent attention of a physician in case of symptoms: fever, nausea, loss of appetite, and itching.
Cronos Group Inc (NASDAQ:CRON) steps up efforts to offer cannabis experience to the users in the form…
Aurora Deutschland, a subsidiary of Aurora Cannabis Inc (NYSE:ACB), has bagged a second order from Luxembourg…
Canopy Growth Corp (NYSE:CGC), a company specializing in the production and distribution of cannabis,…
Hexo Corp (NYSE:HEXO), a company focused in the production and distribution of packaged cannabis products,…
Published at Thu, 16 May 2019 12:01:11 +0000